

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
PAIVI JANNA KUKKOLA

Art Unit: 1611

Examiner: R. Raymond

APPLICATION NO: 09/533,219

FILED: MARCH 23, 2000

FOR: THYROMIMETIC ORGANIC COMPOUNDS

Assistant Commissioner for Patents
Washington, D.C. 20231RECEIVED
OCT 25 11:11:00
1001 CENTRAL EXP/2900SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis Corporation.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the documents cited on the attached form(s) PTO-1449.


Copies of these documents are enclosed herewith.

It has been noted that International application WO 00/51971 published September 8, 2000 (U.S. priority application 60/122,292 filed March 1, 1999) discloses subject matter which overlaps with subject matter disclosed in the instant application, with respect to the compounds of formula I of WO 00/51971 wherein W is O or S(O)_d, and R⁴ is -S(O)₂NR⁹R¹⁰, -C(O)NR⁹R¹⁰ or -S(O)_aR¹². However, it is believed not to be available as a reference against the instant application which was filed March 23, 2000 and claims the benefit of provisional application 60/183,030 filed March 29, 1999.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6926



Norbert Gruenfeld
Agent for Applicant
Reg. No. 30,061

Date: October 23, 2000